EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Annual 12‐Week Dosing Gap of Natalizumab: Clinical Efficacy, Blood Biomarkers, and CSF Cell Composition

Regina Berkovich, Tilman Schneider-Hohendorf iD, Eric Baetscher iD, Evan L Riddle, Marie Deffner, Emily Katsnelson, Janine Ferrant-Orgettas, Julie Czerkowicz, John Anderson, Susan E Goelz, Nicholas Schwab iD

Annals of Clinical and Translational Neurology · 2026

DOI: 10.1002/acn3.70207 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Annals of Clinical and Translational Neurology, 2026. Verfasst von Regina Berkovich und 10 weiteren Autor:innen. Beteiligte Einrichtung: Berkovich MS Center and Research Institute, West Hollywood, California, USA. Hauptthemen laut MEDLINE: Natalizumab, Immunologic Factors, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Biogen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Natalizumab (NTZ) is a highly effective therapy for multiple sclerosis (MS); however, its use is limited by the risk of a rare potentially severe opportunistic brain infection, progressive multifocal leukoencephalopathy (PML). Alternative dosing strategies are evaluated to reduce PML risk while still maintaining efficacy, which include extending the dosing interval (EID) or a lesser‐known annual dosing gap (aGAP), which is the focus of this prospective observational single‐site cohort study. We evaluated whether aGAP affects the efficacy of NTZ, which biomarkers could be useful for a personalized dosing strategy, and potential cellular mechanisms that might contribute to reducing the risk of PML during aGAP.

Methods

Clinical assessments, quantifications of NTZ, neurofilament light chain (NfL), and soluble vascular cell adhesion molecule‐1 (sVCAM‐1) were performed for ten study participants of a clinical trial (NCT04048577); CSF single‐cell RNA‐sequencing data from nine participants (15 samples) were analyzed together with 48 healthy and 35 MS controls.

Results

Although NTZ serum levels were decreased below EID levels and sVCAM‐1 levels were increased, aGAP was not associated with MS activity as measured by EDSS and MRI. After aGAP, while CSF cell counts remained stable, the CSF immune cell composition changed and NfL values were increased 3 months post gap. CSF proportions of CD4, CD8, and natural killer cell subsets increased towards levels of untreated MS patients, while B‐cell proportions remained unchanged.

Interpretation

The differential CSF composition associated with sVCAM‐1 serum level changes suggests that selective immune cell trafficking may occur during aGAP, potentially contributing to PML prevention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NatalizumabImmunologic FactorsMultiple SclerosisMultiple Sclerosis, Relapsing-RemittingLeukoencephalopathy, Progressive MultifocalHumansAdultFemaleMaleBiomarkersMiddle AgedProspective StudiesNeurofilament ProteinsVascular Cell Adhesion Molecule-1

Stichwörter der Autor:innen

alternative dosingmultiple sclerosisnatalizumabpersonalized medicineprogressive multifocal leukoencephalopathy

Substanzen

NatalizumabBiomarkersImmunologic Factorsneurofilament protein LNeurofilament ProteinsVascular Cell Adhesion Molecule-1

Autor:innen und Institutionen

  • Berkovich MS Center and Research Institute, West Hollywood, California, USA.
  • Department of Neurology, University Hospital Münster, Münster, Germany.
  • Advanced Imaging Research Center, Oregon Health & Science University, Portland, Oregon, USA.
  • Biogen, Cambridge, Massachusetts, USA.
  • Oregon Health & Science University, Portland, Oregon, USA.

ORCID-Profile: Tilman Schneider-Hohendorf, Eric Baetscher, Nicholas Schwab

Förderung

  • Biogen

Zitieren

APA

Berkovich, R., Schneider-Hohendorf, T., Baetscher, E., Riddle, E. L., Deffner, M., Katsnelson, E., Ferrant-Orgettas, J., Czerkowicz, J., Anderson, J., Goelz, S. E., & Schwab, N. (2026). Annual 12‐Week Dosing Gap of Natalizumab: Clinical Efficacy, Blood Biomarkers, and CSF Cell Composition. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70207

Vancouver

Berkovich R, Schneider-Hohendorf T, Baetscher E, Riddle EL, Deffner M, Katsnelson E, et al. Annual 12‐Week Dosing Gap of Natalizumab: Clinical Efficacy, Blood Biomarkers, and CSF Cell Composition. Annals of Clinical and Translational Neurology. 2026. doi:10.1002/acn3.70207

BibTeX
@article{Berkovich2026,
  author = {Berkovich, Regina and Schneider-Hohendorf, Tilman and Baetscher, Eric and Riddle, Evan L and Deffner, Marie and Katsnelson, Emily and Ferrant-Orgettas, Janine and Czerkowicz, Julie and Anderson, John and Goelz, Susan E and Schwab, Nicholas},
  title = {Annual 12‐Week Dosing Gap of Natalizumab: Clinical Efficacy, Blood Biomarkers, and CSF Cell Composition},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  doi = {10.1002/acn3.70207}
}
Kostenlos starten →